跳至主要内容
临床试验/NCT02367716
NCT02367716已完成不适用

Post-market Study of Multi-Vector Left Ventricular Lead Performance in Chinese Patients With Chronic Heart Failure

Abbott Medical Devices14 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2014年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
121
试验地点
14
主要终点
The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)

研究概览

简要总结

The purpose of this clinical study is to observe the safety and efficacy of the multi-vector left ventricular (LV) lead in Chinese patients that are indicated for Cardiac Resynchronization Therapy (CRT).

详细描述

This is a multi-center, non-randomized observational study.

The total duration of the study is expected to be 2.5 years. The clinical study will be conducted in no more than 15 centers in China. Approximately 120 subjects will be enrolled in this study. Subjects will be followed up at 3, 6, 12 months and every 6 months afterwards. All subjects need to be followed for at least 6 months.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meets the current European Society of Cardiology (ESC) or American College of Cardiology Foundation (ACCF)/American Heart Association (AHA)/Heart Rhythm Society (HRS) Class I or Class IIa indications for CRT implant (including upgrades from single or dual chamber Implantable Cardioverter-Defibrillators (ICDs))
  • Are ≥ 18 years of age at the time of enrolment.
  • Are able to provide written Informed Consent prior to any study related procedure.

排除标准

  • Patient who is unable to comply with the follow-up schedule.
  • Patient who has any medical conditions that in the opinion of the investigator will not be appropriate to participate in the study .
  • Patient has a life expectancy of less than 1 year due to any condition.
  • Patients, who has a CRT device implanted

结局指标

主要结局

The Number of Participants With LV Lead-related Serious Adverse Device Effects (SADEs)

时间窗: From implantation to 6 months after implant procedure.

The primary safety endpoint is the number of participants with LV lead-related SADEs compared to the total number of analyzed participants.

次要结局

  • The Intrinsic QRS Duration of Participants(6 months)
  • The Number of Participants With Effective LV Pacing(6 months)
  • The Number of Participants in Each NYHA Functional Class(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验